Follow-up: Documentation that appears only after payment

Coming back to post #13, because the follow-up matters more than the original answer.

Exaggerated claims without documentation: every compound has limits. No peptide is "100% pure" because purity is measured to finite precision. A supplier claiming implausible perfection without backing evidence is overreaching.

Picking up post #13: that is the part I would want checked first.

Pricing patterns: unusually low prices for what are otherwise consistent with market rates might indicate lower quality, stolen goods, or a scam. Unusually high prices without justification raise different flags.

Inconsistency across documents: a certificate stating one purity, a website claiming another, and a supplier's verbal representation claiming a third, all on the same product, is a red flag for either incompetence or deception.

Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.

I read post #17 twice before replying, because I had assumed the opposite.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

Inability to trace lots: if you ask "where was this synthesised, by whom, under what conditions" and cannot get a clear answer, that is a red flag. Traceability is not glamorous but it is foundational.

I disagree with the reply above, and I think the disagreement is substantive rather than terminological.

The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.

Unresponsiveness: a supplier that does not reply to reasonable requests for documentation or clarification is showing you something about how they operate.

Safety documentation absent: a supplier that cannot provide information about sterility testing, endotoxin testing, or safety documentation when asked is raising flags.

Worth separating two things that post #20 runs together.

Anonymity: a supplier that will not disclose legal name, address, or responsible person is not operating in a way that allows accountability.

Documentation quality as a signal: a supplier that reports method identifiers, distinguishes specification from result, and states the counter-ion form is telling you something about systems behind the document. A certificate that is a number and a signature tells you less.

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

post #26 answers the question as asked. The question underneath it is different.

Rapid supplier turnover: a supplier that changes corporate structure, domain name, or contact repeatedly in short time windows raises suspicion about stability and legitimacy.

On post #24 — agreed on the reasoning, with one qualification.

Evasion when asked: if a supplier does not clarify when asked specifically for method details, counter-ion form, or batch origin, that itself is a red flag worth documenting.

This follows post #26 rather than contradicting it.

Patterns that reliably precede a problem: underdosing (less active material than stated, documented by independent testing), mislabelling (wrong compound, wrong strength, or wrong batch on the label), and failure to provide documentation when asked.

I read post #28 twice before replying, because I had assumed the opposite.

Inability to trace lots: if you ask "where was this synthesised, by whom, under what conditions" and cannot get a clear answer, that is a red flag. Traceability is not glamorous but it is foundational.